chrisvoncsefalvay/vaers-outcomes huggingface dataset:
2nd Vaccine infected me with horrible large hives with high Histamine Intolerance; 2nd Vaccine infected me with horrible large hives with high Histamine Intolerance; This spontaneous case was reported by a patient and describes the occurrence of HISTAMINE INTOLERANCE (2nd Vaccine infected me with horrible large hives with high Histamine Intolerance) and URTICARIA (2nd Vaccine infected me with horrible large hives with high Histamine Intolerance) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. In April 2022, the patient experienced HISTAMINE INTOLERANCE (2nd Vaccine infected me with horrible large hives with high Histamine Intolerance) and URTICARIA (2nd Vaccine infected me with horrible large hives with high Histamine Intolerance). At the time of the report, HISTAMINE INTOLERANCE (2nd Vaccine infected me with horrible large hives with high Histamine Intolerance) and URTICARIA (2nd Vaccine infected me with horrible large hives with high Histamine Intolerance) had not resolved.            No concomitant product use was reported.  The patient stated Covid-19 moderna 2nd vaccine infected patient with horrible large hives with high histamine Intolerance. The patient had it since 3 months and it was getting worst. The patient never had allergies before.  The patient was going to the doctor, but the medications are not helping. The patient contacted the CDC.
Periodic numbness and tingling (pins and needles) in hands and feet, particularly right hand and right foot.; Worsening of pre-existing inflammation or "carpal tunnel" symptoms in the right hand.; Periodic numbness; Worsening of pre-existing inflammation or "carpal tunnel" symptoms in the right hand.; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the right arm on 14Apr2021 at 11:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. No medical history was reported. The patient previously received sulfamethoxazole; trimethoprim (BACTRIM), desogestrel; ethinylestradiol (APRI) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included postpartum mood support and standard process adrenal on unknown dates, for unknown indications and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 15Apr2021, the patient experienced periodic numbness and tingling (pins and needles) in hands and feet, particularly right hand and right foot and on an unknown date in Apr2021, patient experienced worsening of pre-existing inflammation or carpal tunnel symptoms in the right hand. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of these events. These events did not result in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events worsening carpal tunnel symptoms, tingling (pins and needles) in hands and feet and period numbness were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Started having shortness of breath and dyspnea on exertion on 7/26/21, was tested positive with COVID-19 on 7/28. Pt also has bilateral pulmonary emboli with a saddle pulmonary embolism. Pt was admitted to ICU.
Information has been received from a health professional concerning an approximately 8-year-old male who was vaccinated with a 0.5mL dose of varicella virus vaccine live (Oka/Merck). Subsequently, on approximately 06-NOV-2006, the patient experienced breakthrough and had about 15 to 20 lesions. Unspecified medical attention was sought. No further information was provided. There was no product quality complaint. Additional information has been requested.
dec appetite, limp, dec color, nl cardiac exam @ 111 28MAY, irritable, but dec tone;
Fever; Really painful arm; This case was reported by a consumer via interactive digital media and described the occurrence of fever in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 29th September 2021, the patient received the 1st dose of Shingles vaccine. On 29th September 2021, less than a day after receiving Shingles vaccine, the patient experienced fever and pain in arm. On an unknown date, the outcome of the fever and pain in arm were not recovered/not resolved.   It was unknown if the reporter considered the fever and pain in arm to be related to Shingles vaccine.  Additional details were reported as follows: This case was reported by the patient. The age at vaccination was not reported. The patient received shingles vaccine on the day of reporting and had fever and really painful arm. The follow up would not possible as contacts information was not available.
she started experiencing redness at the injection site; she started experiencing swelling at the injection site; bruising at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (she started experiencing redness at the injection site), VACCINATION SITE SWELLING (she started experiencing swelling at the injection site) and VACCINATION SITE BRUISING (bruising at the injection site) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in February 2022. Concomitant products included ETHINYLESTRADIOL, ETONOGESTREL (NUVARING) for Birth control.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (she started experiencing redness at the injection site), VACCINATION SITE SWELLING (she started experiencing swelling at the injection site) and VACCINATION SITE BRUISING (bruising at the injection site). At the time of the report, VACCINATION SITE ERYTHEMA (she started experiencing redness at the injection site) and VACCINATION SITE SWELLING (she started experiencing swelling at the injection site) had resolved and VACCINATION SITE BRUISING (bruising at the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient information height 5.6 It was reported as patient received her first dose and now there's bruising around the indentation. It hurts in that area and was getting worse. patient said that there was no muscle in that area anymore as there is a big indentation there,  finally saw a doctor today for this issue. patient had notexperienced a similar event in the past. No treatment information was provided by the reporter.   This case was linked to MOD-2022-538690 (Patient Link).
Donor left Dr office after getting tetanus shot to return to reception area; he was in hallway and passed out approx 5 seconds. Pt experienced slight seizure-like movements for approx 3-5 seconds. Transported via wheelchair to Dr office and transported to bed - shock position. Recovered in less than 15 minutes.
Pain at area of injection, chills, night sweats. Came to clinic to be seen at 9:30 AM. Now is having difficulty lifting right arm. Reports pain and localized deltoid (R) area and armpit.
Pt recvd vax on 18FEB83 & APR83 & April or May 1983 exp numbness in big toes & feet; mid MAY83 exp urticaria & swelling of rt foot & leg followed by swelling of upper lip & bronchial constrictions; also angioedema;
9MAR 4PM MOC called back pt had broken out w/a rash w/in minutes of leaving clinic; mom described rash as fine red bumps on lt arm & neck, part of chest & face (lt side) no fever or swelling;
prescription was written for patient intentionally even though she is under age 50; This case was reported by a consumer via call center representative and described the occurrence of off label use in a 35-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced off label use. On an unknown date, the outcome of the off label use was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The patient herself reported the case. The patient had shingles in past. It was stated that Shingrix prescription was written for patient intentionally even though patient was under age 50 and pharmacy refused to administered it,which led to off lable use. The patient stated that her primary care doctor and her rheumatologist both want her to get the vaccine and patient did not know the date the prescription was written. The patient stated that Shingrix was originally only for age 50 years and older but the package insert has been updated recently and it was now approved in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy and patient stated that she fall into that category. The patient did not go into any specific details as to why she was seeing a rheumatologist or if she was currently taking a medication which causes immunosuppression or if she has an immunodeficiency. The patient's doctor wrote patient's script but pharmacy won't fill it and insurance won't cover it. It was stated that the script was written (over 2 months ago) prior to the package insert indication change and patient stated that she already had shingles and She was out of work for 2 months because her shingles case was so severe.  The patient had 3 eye doctor appointments, 8 primary care appointments and 1 emergency room visit and because if that Doctors were really worried about her getting another outbreak and for that Shingrix was prescribed.
Swollen lymph node on left side where injection was given near neck and collar bone with some soreness; Swollen lymph node on left side where injection was given near neck and collar bone with some soreness; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8735) via an unspecified route of administration on 02Sep2021 at 15:45 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included nifedipine (PROCARDIA) and vitamin d (MANUFACTURER UNKNOWN); both for unknown indications from unknown dates and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: FD8448) via an unspecified route of administration on 11Aug2021 at 15:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 04Sep2021 at 09:45, the patient experienced swollen lymph node on left side where injection was given near neck and collar bone with some soreness. The adverse events resulted in emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swollen lymph node on left side where injection was given near neck and collar bone with some soreness was unknown at the time of this report.
had suffered branch retinal arterial occlusions (BRAO) in both eyes; under treatment for retinal vasculitis and possible Susac's syndrome; under treatment for retinal vasculitis and possible Susac's syndrome; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41-year-old male patient received BNT162b2 (BNT162B2), on 14Apr2021 as dose 2, single (Lot number: ER8729) at the age of 41 years, in left arm for COVID-19 immunization. The patient's relevant medical history was not reported. Concomitant medication(s) included: TESTOSTERONE CYPIONATE; HCG. Vaccination history included: BNT162b2 (Dose Number: 1, Batch/Lot No: ER8730, Location of injection: Arm Left), administration date: 24Mar2021, when the patient was 41-year-old, for COVID-19 immunization. The following information was reported: RETINAL VASCULITIS (medically significant), SUSAC'S SYNDROME (medically significant) all with onset 2021, outcome "not recovered" and all described as "under treatment for retinal vasculitis and possible Susac's syndrome"; RETINAL ARTERY OCCLUSION (medically significant) with onset 04Sep2021 at 09:00, outcome "not recovered", described as "had suffered branch retinal arterial occlusions (BRAO) in both eyes". The patient underwent the following laboratory tests and procedures: Fluorescence angiogram: confirmed another BRAO. Therapeutic measures were taken as a result of retinal vasculitis, retinal artery occlusion, Susac's syndrome.  Clinical course: The patient had no other vaccine in four weeks, had no COVID prior to vaccination, and had no known allergies. Other medication in two weeks also included multivitamins. On 04Sep2021, the patient noticed a blind spot in his right eye. After seeking treatment, he was told that he had suffered branch retinal arterial occlusions (BRAO) in both eyes, but his right eye was the most affected, with a noticeable scotoma (blind spot). He had since been under treatment for retinal vasculitis and possible Susac's syndrome. On 05Nov2022, he noticed another scotoma to his right eye. A flourescien angiogram confirmed another BRAO. The patient was currently undergoing aggressive immunosuppressive treatments and has been hospitalized three times since his first episode.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300008410 Same patient, different vaccine dose, different events;
On 8/3/06 took MMR/varicella 1, Hep A, Fever on 8/31, 9/1 next day rash, ER rash spread scarlet fever, Moxifloxacin, 9/5 groggy, eyes turning around. ER Wed06 where she was diagnosed with encephalitis. DC DX for DOS 09/06-09/011/06: Cerebellitis. New onset of inability to stand, face twitching and rapid eye movements. Temp max 100.4 and rash in diaper area. Rash spread over her body and 5 days PTA mother brought her to urgent care center and received amoxicillin. HX: negative for diarrhea, emesis. ER note indicated patient DX with scarlett fever on Thursday. Neuro: started on menigitic doses of ceftriaxone and Acyclovir. Cetriaxone continued until CSF culture negative 48 hours and acyclovir was continued until HSV PCR was negative. Evaluated by ID recommended extensive testing for cause of cerebrillitis. Eye movements and ataxia improved.. Ophto exam much improved with only occasional saccades.
dizziness, headache, shortness of breath, body aches, increased heart rate within 30 minutes injection. only treatment taken naproxin
Felt like she was "having a panic attack" and was then lowered to the ground with lightheadedness. Did not loose consciousness.
slept all day and night; was feeling pretty bad/still don't feel good; bodyaches /  feels like he got punched in the arm; nausea / still have nausea; headache / still have headache; sick; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (sick), SOMNOLENCE (slept all day and night), MALAISE (was feeling pretty bad/still don't feel good), MYALGIA (bodyaches /  feels like he got punched in the arm) and NAUSEA (nausea / still have nausea) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 08-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jun-2021, the patient experienced ILLNESS (sick), MYALGIA (bodyaches /  feels like he got punched in the arm), NAUSEA (nausea / still have nausea) and HEADACHE (headache / still have headache). On an unknown date, the patient experienced SOMNOLENCE (slept all day and night) and MALAISE (was feeling pretty bad/still don't feel good). The patient was treated with BISMUTH SUBSALICYLATE (PEPTO BISMOL [BISMUTH SUBSALICYLATE]) ongoing since an unknown date for Headache, at a dose of 1 dosage form and NAPROXEN ongoing since an unknown date for Headache, at a dose of 1 dosage form. At the time of the report, ILLNESS (sick), SOMNOLENCE (slept all day and night), MALAISE (was feeling pretty bad/still don't feel good), MYALGIA (bodyaches /  feels like he got punched in the arm), NAUSEA (nausea / still have nausea) and HEADACHE (headache / still have headache) had not resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Concomitant medicines were not reported   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: Updated Reporter details, Patient demographics, Added vaccination details , Treatment medications, Added new event Somnolence
Stuffy nose; Stuffy head; Cough because of postnasal drip; Tightness; Wheezing; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of NASAL CONGESTION (Stuffy nose), HEAD DISCOMFORT (Stuffy head), COUGH (Cough because of postnasal drip), CHEST DISCOMFORT (Tightness) and WHEEZING (Wheezing) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no medical history provided).    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NASAL CONGESTION (Stuffy nose), HEAD DISCOMFORT (Stuffy head), COUGH (Cough because of postnasal drip), CHEST DISCOMFORT (Tightness) and WHEEZING (Wheezing). The patient was treated with VITAMIN C [ASCORBIC ACID] for Calcium supplementation, at an unspecified dose and frequency; VITAMIN D [VITAMIN D NOS] for Vitamin supplementation, at an unspecified dose and frequency; AZITHROMYCIN (Z-PAK) for Wheezing, Cough and Head discomfort, at an unspecified dose and frequency and ZINC for Supplementation therapy, at an unspecified dose and frequency. At the time of the report, NASAL CONGESTION (Stuffy nose), HEAD DISCOMFORT (Stuffy head), COUGH (Cough because of postnasal drip), CHEST DISCOMFORT (Tightness) and WHEEZING (Wheezing) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Jan-2021, SARS-CoV-2 test: positive positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant medication provided. Patient used mucus relief
On the day of the vaccine was given, the patient developed chills, lightheadedness, dizziness, weakness and body aches. She also complained of shortness of breath. Temp was 105 degrees. Felt better in morning, consulted with provider by phone who advised her to increase fluids, take TYLENOL and call if worsens.
Around 5PM I started to get chills and body aches. Later that night I had a fever of high 103F, chills, nausea, body aches, could barely move or lift my right arm. I felt worse than I did when I actually had covid back in December.
pt recv vax around 10AM;temp of 104 @ 1PM;sz around 12MD;taken to ER prescribed meds;
This spontaneous report as received from a other health professional refers to a patient of unknown age. On 18-MAY-2017 the patient was vaccinated with RECOMBIVAX HB lot # L038018 for prophylaxis. Other suspect therapies included ROTATEQ. Concomitant therapies included hib conj vaccine (unspecified carrier), diphtheria toxoid, pertussis acellular vaccine (unspecified), poliovirus vaccine inactivated (unspecified), tetanus toxoid(DIPHTHERIA TOXOID (+) HIB CONJ VACCINE (UNSPECIFIED CARRIER) (+) PERTU) and PREVNAR 13. On 2017 the patient experienced incorrect product storage.  On an unknown date the patient experienced no adverse event. The outcome of incorrect product storage and no adverse event is unknown. The reporter considered no adverse event to be not related to RECOMBIVAX HB and ROTATEQ. The reporter considered incorrect product storage to be not related to ROTATEQ and RECOMBIVAX HB. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1707USA006507.
dose given beyond 30-day expiration date; dose given beyond 30-day expiration date; No adverse event; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (dose given beyond 30-day expiration date), PRODUCT STORAGE ERROR (dose given beyond 30-day expiration date) and NO ADVERSE EVENT (No adverse event) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR9236B) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (dose given beyond 30-day expiration date), PRODUCT STORAGE ERROR (dose given beyond 30-day expiration date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (dose given beyond 30-day expiration date), PRODUCT STORAGE ERROR (dose given beyond 30-day expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (dose given beyond 30-day expiration date) and PRODUCT STORAGE ERROR (dose given beyond 30-day expiration date).    Concomitant products were not reported.  It was reported the vial was initially stored in the refrigerator on 13-Sep-2022 and administered on 18-Oct, 25-Oct, 01-Nov, 02-Nov and 08-Nov. The vial did not underwent any temperature excursion. It was unknown if individual vials or unbroken cartons were used. The vial size was unknown.  Treatment medications were not reported.
I was trying to sleep last night after drinking a glass of water before bed, which is my usual routine. After going to bed, I woke up with my body vigorously shaking, starting from the location of the injection site. I had to hold onto my neck oh the left side for support due to all the muscles, spreading from the injection site, wanting to vigorously contract and pull hard towards the injection location. My heart rapidly beat and I had to take the time to try and calm the body by doing deep breathing exercises. When it got to a comfortable time to move, I went to use the restroom and had to drink lots of water due to feeling a temperature, light sensitivity, a head ache, and body fatigue. This pattern happened throughout the night several times to the point where I felt sick. After my body calmed mostly down, I called the pharmacist at Genoa to share my experience. They mentioned how it was normal and to take a Tylenol to help with the symptoms. I also had to call in sick to work and request a substitute teacher to help with my classes today.